Novel therapeutic agents in acute myeloid leukemia

Schiffer, 2006 Stone, 2002, The difficult problem of acute myeloid leukemia in the older adult, CA Cancer J Clin, 52, 363, 10.3322/canjclin.52.6.363 Bennett, 1985, Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group, Ann Intern Med, 103, 620, 10.7326/0003-4819-103-4-620 Harris, 1999, World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997, J Clin Oncol, 17, 3835, 10.1200/JCO.1999.17.12.3835 Grimwade, 1998, The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trail. The Medical Research Council Adult and Children's Leukemia Working Parties, Blood, 92, 2322, 10.1182/blood.V92.7.2322 Tallman, 2002, Acute promyelocytic leukemia: evolving therapeutic strategies, Blood, 99, 759, 10.1182/blood.V99.3.759 Soignet, 2001, United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia, J Clin Oncol, 19, 3852, 10.1200/JCO.2001.19.18.3852 Sievers, 2001, Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse, Exp Opin Biol Ther, 1, 893, 10.1517/14712598.1.5.893 Kelly, 2002, Genetics of myeloid leukemias, Annu Rev Genomics Hum Genet, 3, 179, 10.1146/annurev.genom.3.032802.115046 Lancet, 2003, Farnesyl transferase inhibitors in myeloid malignancies, Blood, 17, 123, 10.1016/S0268-960X(03)00008-0 Karp, 2001, Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial, Blood, 97, 3361, 10.1182/blood.V97.11.3361 Harousseau, 2003, Zarnestra (R115777) in patients with relapsed and refractory acute myelogenous leukemia (AML): results of a multicenter Phase II study, Blood, 102 Lancet, 2004, Tipifarnib (Zarnestra™) in previously untreated poor-risk AML of the elderly: updated results of a multicenter Phase II trial, Blood, 104, 10.1182/blood.V104.11.874.874 Gilliland, 2002, The roles of FLT3 in hematopoiesis and leukemia, Blood, 100, 1532, 10.1182/blood-2002-02-0492 Kottaridis, 2001, Blood, 98, 1752, 10.1182/blood.V98.6.1752 Weisberg, 2002, Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412, Cancer Cell, 1, 433, 10.1016/S1535-6108(02)00069-7 Kelly, 2002, FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model, Blood, 99, 310, 10.1182/blood.V99.1.310 Kelly, 2002, CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML), Cancer Cell, 1, 421, 10.1016/S1535-6108(02)00070-3 De Angelo, 2003, Phase I clinical results with MLN518, a novel FLT3 antagonist: tolerability, pharmacokinetics, and pharmacodynamics, Blood, 102 De Angelo, 2004, Phase II evaluation of the tyrosine kinase inhibitor MLN518 in patients with acute myeloid leukemia (AML) bearing a FLT3 internal tandem duplication (ITD) mutation, Blood, 104, 10.1182/blood.V104.11.1792.1792 Smith, 2004, Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia, Blood, 103, 3669, 10.1182/blood-2003-11-3775 Stone, 2005, Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412, Blood, 105, 54, 10.1182/blood-2004-03-0891 Heidel, 2006, Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain, Blood, 107, 293, 10.1182/blood-2005-06-2469 Propper, 2001, Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C, J Clin Oncol, 19, 1485, 10.1200/JCO.2001.19.5.1485 Levis, 2004, In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects, Blood, 104, 1145, 10.1182/blood-2004-01-0388 Stone, 2005, Phase IB study of PKC412, an oral FLT3 kinase inhibitor, in sequential and simultaneous combinations with daunorubicin and cytarabine (DA) Induction and high-dose cytarabine consolidation in newly diagnosed patients with AML, Blood, 106, 10.1182/blood.V106.11.404.404 Levis, 2005, Pharmacokinetic and pharmacodynamic studies of lestaurtinib (CEP-701) and PKC-412: cytotoxicity is often dependent on non-FLT3-mediated effects, Blood, 106 George, 2004, Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3, Cancer Res, 64, 3645, 10.1158/0008-5472.CAN-04-0006 Baer, 2002, Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720, Blood, 100, 1224, 10.1182/blood.V100.4.1224.h81602001224_1224_1232 List, 2001, Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study, Blood, 98, 3212, 10.1182/blood.V98.12.3212 Marcucci, 2004, G3139, a BCL-2 antisense oligo-nucleotide, in AML, Ann Hematol, 83, S93 Karp, 2004, Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab, Clin Cancer Res, 10, 3577, 10.1158/1078-0432.CCR-03-0627 Lowenberg, 2003, Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia, N Engl J Med, 349, 743, 10.1056/NEJMoa025406 Bross, 2001, Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia, Clin Cancer Res, 7, 1490 Wadleigh, 2003, Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation, Blood, 102, 1578, 10.1182/blood-2003-01-0255 Feldman, 2005, Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia, J Clin Oncol, 23, 4110, 10.1200/JCO.2005.09.133 Heslop, 2003, Immunotherapy of hematologic malignancy, Hematology Am Soc Hematol Educ Program, 331, 10.1182/asheducation-2003.1.331 Gong, 2004, Induction of anti-leukemic cytotoxic T lymphocytes by fusion of patient-derived dendritic cells with autologous myeloblasts, Leuk Res, 28, 1303, 10.1016/j.leukres.2004.03.018 Alyea, 2005, Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age, Blood, 105, 1810, 10.1182/blood-2004-05-1947 Giles, 2004, A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia, Clin Cancer Res, 10, 2908, 10.1158/1078-0432.CCR-03-0738 Giles, 2003, Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase, Leuk Res, 27, 1091, 10.1016/S0145-2126(03)00094-8 Kantarjian, 2003, Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia, Blood, 102, 2379, 10.1182/blood-2003-03-0925